Every Form 4 that ICU Medical Inc (ICUI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ICUI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ICUI filings page.
ICU MEDICAL INC/DE (ICUI) reported that Virginia Ruth Sanzone, its VP, General Counsel, sold a total of 4,856 shares of common stock on September 3, 2026 in four open-market or private transactions pursuant to a Rule 10b5-1 trading plan adopted on June 8, 2026, at weighted average prices ranging from about $167.67 to $171.52 per share.
ICU MEDICAL INC/DE (ICUI) reported that Chief Financial Officer Brian Michael Bonnell sold 6,381 shares of common stock on September 1, 2026, at $175.00 per share in an open-market or private transaction. After this sale, he directly holds 56,062 shares. The sale was described as involving restricted award shares and was effected under a Rule 10b5-1 trading plan adopted on June 1, 2026, with all shares sold at the exact disclosed price.
ICU MEDICAL INC/DE (ICUI) reported that Chief Financial Officer Brian Michael Bonnell sold a total of 9,307 shares of common stock on August 31, 2026 in four open-market transactions. The sales, related to a restricted award, were effected under a Rule 10b5-1 trading plan adopted on June 1, 2026, at weighted average prices ranging from about $170.57 to $174.08 per share, each executed over multiple trades within the stated price ranges.
ICU Medical Inc. (ICUI) officer Daniel Woolson, VP and GM-Infusion Capital, reported a sale of 5,417 shares of common stock on August 13, 2026 at $181.33 per share. Following this transaction, he directly holds 17,062 shares of ICU Medical common stock. The Rule 10b5-1 trading plan checkbox was not marked.
ICU Medical Inc/DE Chief Information Officer Ben Sousa reported a sale of 2,250 shares of common stock on 2026-08-12 in an open market or private transaction. The shares were sold at $178.3152 per share, leaving him with 3,076 shares of directly held common stock.
ICU Medical Inc. (ICUI) Chief Operating Officer Christian B. Voigtlander reported an open-market sale of 8,929 shares of common stock on 2026-08-11 at a weighted average price of $182.93 per share, with individual trade prices ranging from $182.85 to $183.03. Following this transaction, he directly owns 37,377 shares of ICU Medical common stock.
ICU Medical Inc. director Elisha W. Finney sold common shares, disposing of 378 shares of ICU Medical Inc. common stock on 2026-08-11 in an open market or private transaction at a weighted average price of $182.4818 per share. The trades occurred in a price range from $182.4808 to $182.5701. Following this transaction, Finney directly holds 4,871 common shares of ICU Medical Inc.
ICU Medical Inc. President Daniel Woolson reported an open-market sale of 2,123 shares of Common Stock. The shares were sold at a weighted average price of $132.2114 per share, with individual trade prices ranging from $132.03 to $132.33. After this transaction, Woolson directly holds 22,479 shares of ICU Medical common stock. The filing notes that detailed trade-by-trade pricing information is available upon request.
ICU Medical Inc. executive reports stock sale. VP and General Counsel Virginia Ruth Sanzone sold 2,447 shares of ICU Medical common stock in an open-market sale at $124.08 per share. After this transaction, she directly holds 19,460 shares, so the sale represents a modest portion of her overall position.
ICU Medical director Kolleen T. Kennedy reported compensation-related equity activity in the company’s stock. On May 13, 2026, 1,254 Restricted Stock Units vested and were settled into an equal number of ICU Medical common shares, bringing her direct holdings to 4,539 shares.
On the same date, Kennedy also received a new grant of 1,475 Restricted Stock Units. According to the disclosure, these units have no purchase or exercise price and will vest on the anniversary of the grant date or at the following annual stockholder meeting, whichever occurs first.
ICU Medical director Laurie Hernandez reported routine equity compensation activity. On May 13, 2026, she exercised 1,254 Restricted Stock Units into Common Stock, bringing her direct holdings to 4,862 shares.
On the same date, she received a new grant of 1,475 Restricted Stock Units, which vest on the anniversary of the grant or the following stockholder meeting, whichever occurs first. The Restricted Stock Units have no purchase or exercise price.
ICU Medical director Elisha W. Finney reported equity compensation activity involving Restricted Stock Units (RSUs). On May 13, 2026, 1,254 RSUs were exercised into the same number of shares of common stock, increasing direct share ownership to 5,249 shares after the transaction. The filing also shows a new award of 1,475 RSUs, which carry no purchase or exercise price and are scheduled to vest on the first anniversary of the grant date or at the next annual stockholder meeting, whichever occurs first. These transactions reflect routine director compensation rather than open-market buying or selling.
ICU Medical director Donald Abbey reported compensation-related equity activity, not open-market trading. On May 13, 2026, Abbey exercised derivative securities to acquire 1,254 shares of Common Stock and received a new grant of 1,475 Restricted Stock Units, which have no purchase or exercise price and vest on the earlier of the grant anniversary or the next annual stockholder meeting. Following these transactions, Abbey directly holds 6,004 shares of Common Stock and 1,475 Restricted Stock Units tied to Common Stock.
ICU Medical director David F. Hoffmeister reported compensation-related equity activity. On May 13, 2026, he acquired 1,254 shares of Common Stock through the exercise of previously granted Restricted Stock Units, bringing his direct holdings to 6,004 shares of Common Stock.
On the same date, he also received a new award of 1,475 Restricted Stock Units. These RSUs have no purchase or exercise price and are scheduled to vest on the anniversary of the grant date or at the following annual stockholder meeting, whichever occurs first. The filing shows no open-market purchases or sales.
ICU Medical director David C. Greenberg reported a mix of option exercises, stock sales, and equity awards. On May 12, 2026, he exercised options for 2,424 shares of common stock at $101.06 per share and sold 2,424 shares at $122.91 per share, leaving 7,960 shares held directly.
On May 13, 2026, 1,254 Restricted Stock Units vested into common stock, increasing his direct holdings to 9,214 shares. He also received a new grant of 1,475 Restricted Stock Units, which have no purchase or exercise price and will vest on the grant anniversary or the next annual stockholder meeting, whichever comes first.
ICU Medical Inc. director Donald Abbey reported an other-type share transfer involving 704 shares of Common Stock. The transaction occurred on March 25, 2026 at a stated price of $0.00 per share and was categorized as an "other acquisition or disposition."
According to the footnote, the shares were transferred pursuant to a domestic relations order, and the reporting person no longer has a reportable beneficial interest in the transferred shares. Following this non-market, personal-transfer event, Abbey directly holds 4,046 shares of ICU Medical common stock.
ICU Medical Chief Operating Officer Christian B. Voigtlander reported compensation-related share activity tied to performance awards. He exercised performance-based restricted stock units and restricted stock units that settled into 14,648 shares of Common Stock, with no purchase or exercise price.
These units were granted on 3/15/2023 and, after the Compensation Committee certified results on 2/11/26, the performance-based awards were earned at 117% of target. To cover tax obligations, 8,096 shares were withheld at $125.85 per share, leaving a net increase of 6,552 shares. Following these transactions, Voigtlander directly owns 46,306 shares of Common Stock.
ICU Medical Inc. executive Daniel Woolson, VP and GM-Infusion Capital, exercised performance-based restricted stock units into common stock. He converted 2,924 performance shares into 2,924 shares of common stock, then had 1,295 of those shares withheld to cover tax obligations at $125.85 per share. After these compensation-related transactions, he holds 24,602 shares of common stock directly, indicating a routine vesting and tax-settlement event rather than an open‑market trade.
ICU Medical Inc. Chief Information Officer Ben Sousa reported compensation-related equity activity involving Restricted Stock Units. On 2026-03-15, 1,300 Restricted Stock Units converted into an equal number of shares of Common Stock at no purchase or exercise price. In a related step, 718 shares were withheld at $125.85 per share to satisfy tax obligations, rather than being sold on the open market. Following these transactions, Sousa directly owned 5,326 shares of ICU Medical Common Stock.
ICU Medical Inc. VP and General Counsel Virginia Ruth Sanzone reported compensation-related equity activity. On March 15, 2026, she settled performance-based restricted stock units and restricted stock units that converted into 7,324 shares of Common Stock.
To cover tax obligations, 4,047 shares were withheld at $125.85 per share, resulting in a net addition of 3,277 shares. Following these transactions, she directly holds 21,907 shares of ICU Medical common stock. The PRSUs, granted on March 15, 2023, were earned at 117% of target after performance certification.
ICU Medical (ICUI) Chairman and CEO Vivek Jain reported equity award activity and related tax withholding. On March 15, 2026, performance-based restricted stock units granted on March 15, 2023 were earned at 117% of target after Compensation Committee certification, resulting in the exercise of derivative awards for 21,972 shares of common stock. To cover tax liabilities, a total of 12,145 shares of common stock were withheld at $125.85 per share, which is not an open-market sale. Following these transactions, Jain directly holds 126,833 shares of common stock and indirectly holds 152,339 shares through a trust.
ICU Medical Chief Financial Officer Brian Michael Bonnell exercised stock awards and settled related taxes in shares. He exercised performance-based restricted stock units and restricted stock units, acquiring 14,648 shares of common stock with no cash exercise price. To cover tax liabilities, 7,595 shares were withheld at $125.85 per share, a non-market disposition. After these compensation-related transactions, he directly owns 71,750 shares of ICU Medical common stock.
ICU Medical Chief Financial Officer Brian Michael Bonnell reported equity award activity involving performance-based and time-based stock units. On March 8, 2026, performance stock units granted on March 8, 2024 were certified at 250% of target, resulting in the acquisition of 71,757 shares of common stock, with no exercise price.
On the same date, 39,667 shares of common stock were disposed of at $132.00 per share to cover tax obligations through share withholding, leaving 64,697 shares directly owned afterward. On March 7, 2026, additional equity awards were settled, including 3,522 shares acquired via derivative exercises and 1,263 shares withheld for taxes, resulting in 32,607 directly owned shares after that date.
ICU Medical Chairman and CEO Vivek Jain reported multiple equity award transactions. On March 8, 2026, he exercised 107,635 performance shares at $0.00 per share, acquiring the same number of common shares, which were earned at 250% of target PRSU performance after Compensation Committee certification.
That same day, 59,500 common shares were disposed of at $132.00 per share to satisfy tax obligations through share withholding, not an open-market sale. On March 7, 2026, he exercised awards covering 5,282 shares twice (derivative and non-derivative reporting), and 2,919 shares were withheld for taxes. Following these events, he also reported 152,339 common shares held indirectly through a trust.
ICU Medical Chief Information Officer Ben Sousa reported multiple equity award transactions. On 3/7/26 and 3/8/26, he acquired common stock through the exercise or settlement of Restricted Stock Units and performance-based Restricted Stock Units, including 7,177 performance shares earned at 250% of target following Compensation Committee certification.
On both dates, some common shares were disposed of in transactions coded “F” at a price of $132 per share, representing shares withheld to satisfy tax obligations rather than open-market sales. After these transactions, Sousa directly owned 4,744 shares of ICU Medical common stock.
ICU Medical (ICUI) VP and General Counsel Virginia Ruth Sanzone reported equity award activity involving restricted and performance-based stock units. On March 7 and 8, 2026, she acquired multiple blocks of Common Stock through exercises or conversions of derivative awards, including 23,917 Performance Shares and several smaller tranches.
The filing also shows dispositions of Common Stock coded as tax-withholding events, with 13,221 shares and 1,762 shares delivered at a price of $132.00 per share to satisfy exercise price or tax liabilities. A performance stock unit grant dated March 8, 2024 was certified at 250% of target on February 11, 2026, resulting in the shares acquired. Footnotes explain that these awards are restricted stock units and performance-based restricted stock units with no purchase or exercise price and time-based vesting over three years.
ICU Medical (ICUI) executive Daniel Woolson reported multiple equity award settlements and related tax-withholding transactions. On March 7–8, 2026, he acquired ICU Medical common stock through the exercise or conversion of performance-based and other restricted stock units at an exercise price of $0.00 per share.
The filing shows Performance-based Restricted Stock Units (PRSUs) granted on March 8, 2024 were earned at 250% of target after the Compensation Committee certified performance results on February 11, 2026, resulting in common shares being issued. Code F entries reflect tax-withholding dispositions of common shares at $132.00 per share, leaving Woolson with directly owned common stock as reported after each transaction.
ICU Medical Chief Operating Officer Christian B. Voigtlander reported equity award activity involving performance-based and time-based stock units. On 3/8/2026, he exercised 71,757 performance shares at $0 per share, converting them into 71,757 shares of common stock, and his direct common stock holdings increased to 79,421 shares.
As part of this activity, 39,667 shares of common stock were disposed of at $132 per share to satisfy tax withholding obligations, leaving 39,754 shares directly owned afterward. On 3/7/2026, he also exercised 3,522 performance-based restricted stock units for 3,522 common shares, with 1,946 shares withheld at $132 per share for taxes. Footnotes explain that these awards are restricted and performance-based units with no purchase or exercise price, and recent performance certification caused the PRSUs granted on 3/8/2024 to be earned at 250% of target.
ICU Medical, Inc. (ICUI) insider transaction: company officer Daniel Woolson, listed as VP, GM-Infusion Capital, reported selling 2,897 shares of ICUI common stock in an open market transaction on 11/25/2025, at a price of $152.3522 per share. After this sale, he beneficially owns 11,297 shares of ICU Medical common stock.
ICU Medical (ICUI) Form 4: Director Elisha W. Finney exercised 1,285 non-qualified stock options at $103.76 and, on the same day (11/11/2025), sold 1,285 shares at $140.42. Following these transactions, she directly owns 3,995 shares.
The option carried a $103.76 exercise price, became exercisable on 06/15/2016, and expires on 01/08/2026; derivative securities beneficially owned after the transactions were 0.
ICU Medical (ICUI) disclosed a Form 4 reporting an insider sale by officer Virginia Sanzone, VP and General Counsel. She sold 930 shares of common stock on 11/11/2025 at $142.345 per share, coded “S” for sale. Following the transaction, she beneficially owns 5,456 shares, held directly. The filing notes all shares were sold at the exact price disclosed.